Nkarta Inc. (NKTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NKTX Stock Price Chart Interactive Chart >
NKTX Price/Volume Stats
| Current price | $12.67 | 52-week high | $40.64 |
| Prev. close | $12.90 | 52-week low | $7.55 |
| Day low | $12.08 | Volume | 782,600 |
| Day high | $13.14 | Avg. volume | 1,959,380 |
| 50-day MA | $12.52 | Dividend yield | N/A |
| 200-day MA | $17.34 | Market Cap | 418.24M |
Nkarta Inc. (NKTX) Company Bio
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Latest NKTX News From Around the Web
Below are the latest news stories about Nkarta Inc that investors may wish to consider to help them evaluate NKTX as an investment opportunity.
William Blair Initiates a Buy Rating on Nkarta (NKTX)William Blair analyst Sami Corwin initiated coverage with a Buy rating on Nkarta (NKTX – Research Report) today. The company's shares closed last Wednesday at $13.76, close to its 52-week low of $12.46. Currently, the analyst consensus on Nkarta is a Strong Buy with an average price target of $67.00. See Insiders’ Hot Stocks on TipRanks >> Based on Nkarta's latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $22.35 million. In comparison, last year the company had a GAAP net loss of $13.69 million. |
Do Institutions Own Nkarta, Inc. (NASDAQ:NKTX) Shares?Every investor in Nkarta, Inc. ( NASDAQ:NKTX ) should be aware of the most powerful shareholder groups. Institutions... |
Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AMLSOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NKX101 for treatment of acute myeloid leukemia (AML). |
Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and ExpositionSOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today presented a trial in progress poster on NKX019 for the treatment of relapsed and refractory B-cell malignancies at the 63 rd Annual Meeting and Exposition of the American Society of Hematology (ASH). |
Charles Schwab Investment Management Inc. Has $3.41 Million Holdings in Nkarta, Inc. (NASDAQ:NKTX)Charles Schwab Investment Management Inc. reduced its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 9.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,615 shares of the companys stock after selling 11,482 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately [] |
NKTX Price Returns
| 1-mo | 63.06% |
| 3-mo | N/A |
| 6-mo | -27.64% |
| 1-year | -52.19% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -17.46% |
| 2021 | -75.03% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...